Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Ann N Y Acad Sci. 2016 Jul 6;1378(1):68–79. doi: 10.1111/nyas.13120

Figure 4.

Figure 4

Reduction in severity of TMDT symptoms by combined DZP and MK-801 treatment. The figure depicts severity score as a function of dose of the DZP:MK-801 combination treatment. Circles: DZP:MK-801 3:1 fixed ratio doses; solid line: linear regression of these points (R2 = 0.88). Diamond: a 3:1 dose (DZP:MK-801 1.2:0.4 mg/kg), where MK-801 was administered 10 min after DZP administration. This latter regimen provided a significantly improved severity score relative to simultaneous administration of DZP and MK-801 (P = 0.0013, Mann–Whitney U-test). From Ref. 62.